摘要
目的探讨中国经典型多发性硬化(classical multiple sclerosis,CMS)患者β干扰素-1b治疗前后血清尿酸(uricacid,UA)水平的变化及其与复发率、扩展残疾状态评分(Expanded Disability StatusScale,EDSS)和颅内增强病灶(contrast-enhancing lesions,CELs)数目间的关系。方法 12例CMS患者(10例女性,2例男性,年龄:24~54岁)被纳入至一项为期6个月的疗效观察研究。在疾病缓解期,给予β干扰素-1b(250μg,皮下注射,隔日1次)治疗。治疗前后评估患者EDSS评分、年复发次数、颅内CELs数目和血清UA水平。结果治疗后,患者年复发次数(0.0比0.9,P=0.011)和颅内CELs数目(0.0比1.5,P=0.007)较治疗前明显减低;EDSS评分有降低趋势(2.0比2.8),但差异无统计学意义(P=0.064);血清UA水平从222.2μmol/L升高至234.9μmol/L,但差异亦无统计学意义(P=0.213)。进一步研究发现,血清UA水平升高与颅内CELs数目减低显著相关(r=-0.716,P=0.009)。结论血清UA水平有可能成为评估CMS患者对β干扰素-1b治疗反应的一个监测指标。
with relapse rate, Objective To investigate the changes of Expanded Disability Status Scale (EDSS) serum uric acid (UA) level and its relationship score, and the number of contrast-enhancing le- sions (CELs) in Chinese patients with classic multiple sclerosis (CMS) before and after interferon (IFN)-beta 1 b treatment. Methods Twelve patients ( 10 women and 2 men, aged 24 to 54 years) with definite CMS were enrolled into a 6-month open-label observational treatment study. IFN-beta l b (250 μg, qod) was injected subcutaneously during remission stage. EDSS, relapse rate, number of CELs, and serum UA levels were exam- ined both at baseline and at the end of the study. Results After treatment, the median relapse rate (0.0 vs. 0.9, P = 0. 011 ) and median number of CELs (0.0 vs. 1.5, P = 0. 007 ) decreased significantly compared with those before treatment. The median EDSS score also decreased from 2.8 to 2.0, but the difference was not statistically significant ( P = 0. 064 ). Serum UA level increased from 222.2 μmol/L to 239.4 μmol/L after treatment, although the difference was not statistically significant (P = 0. 213 ). However, there was significant correlation between the increase in UA level and the decrease in number of CELs ( r = - 0. 716, P = 0. 009). Conclusions UA may serve as an easily detectable and economic marker for the blood-brain barrier function in CMS patients and for the responses to IFN-beta 1 b treatment.
出处
《协和医学杂志》
2012年第3期282-286,共5页
Medical Journal of Peking Union Medical College Hospital
关键词
多发性硬化
尿酸
Β干扰素
multiple sclerosis
uric acid
interferon-beta